Kenvue Inc(KVUE) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | S&P 500 | P/E | 22.69 | EPS (ttm) | 0.86 | Insider Own | 0.25% | Shs Outstand | 1.92B | Perf Week | 3.49% |
| Market Cap | 37.59B | Forward P/E | 15.71 | EPS next Y | 5.98% | Insider Trans | -0.87% | Shs Float | 1.92B | Perf Month | 11.13% |
| Enterprise Value | 45.09B | PEG | 2.18 | EPS next Q | 0.29 | Inst Own | 96.48% | Short Float | 3.01% | Perf Quarter | 0.46% |
| Income | 1.66B | P/S | 2.44 | EPS this Y | 8.85% | Inst Trans | 1.01% | Short Ratio | 2.55 | Perf Half Y | 11.89% |
| Sales | 15.41B | P/B | 3.56 | EPS next 5Y | 7.19% | ROA | 6.16% | Short Interest | 57.66M | Perf YTD | 13.45% |
| Book/sh | 5.5 | P/C | 33.86 | EPS past 3/5Y | -10.84% - | ROE | 15.58% | 52W High | -2.78% ($20.13) | Perf Year | 29.69% |
| Cash/sh | 0.58 | P/FCF | 19.64 | Sales past 3/5Y | 0.43% 0.89% | ROIC | 9.36% | 52W Low | 39.59% ($14.02) | Perf 3Y | -0.56% |
| Dividend Est. | $0.85 (4.32%) | EV/EBITDA | 12.78 | EPS Y/Y TTM | 16.81% | Gross Margin | 58.36% | Volatility(W/M) | 2.14% 1.73% | Perf 5Y | - |
| Dividend TTM | 1.04 | EV/Sales | 2.93 | Sales Y/Y TTM | 1.75% | Oper. Margin | 19.24% | ATR (14) | 0.38 | Perf 10Y | - |
| Dividend Ex-Date | 2026/9/21 | Quick Ratio | 0.71 | EPS Q/Q | 8.86% | Profit Margin | 10.76% | RSI (14) | 67.44 | Recom | 2.87 |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.01 | Sales Q/Q | 3.02% | SMA20 | 7.64% ($18.18) | Beta | 0.41 | Target Price | $19.3 |
| Payout | 107.98% | Debt/Eq | 0.82 | Earnings | 2026/8/6 | SMA50 | 6.59% ($18.36) | Rel Volume | 0.49 | Prev Close | $19.88 |
| Employees | 22000 | LT Debt/Eq | 0.68 | EPS/Sales Surpr. | -2.73% -0.27% | SMA200 | 7.94% ($18.13) | Avg Volume(3M) | 22.61M | Price | $19.57 |
| IPO | 2023/5/4 | Option/Short | Yes/Yes | Trades | 24390 | Volume | 11,094,413 | Change | -1.56% |
🧴 This is a consumer health-focused company with a portfolio of global consumer health brands, including Tylenol, Listerine, Neutrogena, Neutrogena, Johnson's, Band-Aid, and Aveeno. Since being spun off from Johnson & Johnson, it has been operating its own consumer health business as a global household goods and personal care company.
Over the past 1 year, on the higher side
3% below its 1-year high.
Traded less than usual. That is 49% of its average volume.
KVUE makes money exceptionally well
Of every $100 in sales, $19.24 is kept as operating profit.
Tap to view numbers
Growth is moderate
Earnings are expected to grow by +8.8% this year.
Tap to view numbers
The price is about the industry average
For a company earning $100 a year, you would pay $2,269. Peers typically go for $2,346. It is about in line with its own 3-year average.
Tap to view numbers
It has beaten expectations every time
Beat market estimates in the last 4 quarters.
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Hold.
Tap to view numbers
Holding long would have paid off
Bought 3 years ago, your return today would be -0.6%.
Tap to view numbers
Dividends are more than it earns
It pays out 108% of what it earns.
Tap to view numbers
Ownership looks stable
Institutions hold 96.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #5 of 30 in the industry
Based on market cap of $38B.
FAQ
What kind of company is KVUE?
KVUE belongs to the Consumer Defensive sector and operates in the Household & Personal Products industry.
What is the market cap of KVUE?
The market cap of KVUE is approximately $37.6B, ranking 396 within its sector.
Does KVUE pay dividends?
KVUE has a dividend yield of approximately 4.32%, with an annual dividend of $0.85.
What is the P/E ratio of KVUE?
KVUE has a P/E ratio of approximately 22.7x, which can be used to assess its valuation relative to the Consumer Defensive sector average.
What is the 52-week high and low for KVUE?
KVUE has recorded a 52-week high of $20.13 and a low of $14.02.
